

Not for publication, distribution, or release, directly or indirectly, in whole or in part, within or into the United Kingdom, USA, Canada, Japan, Australia, Hong Kong, New Zealand, Switzerland, South Africa or any other jurisdiction in which such publication, distribution or release may be contravening to any applicable laws or rules. Additional restrictions are applicable, please see "important information" in the end of this press release.

Precise Biometrics publishes prospectus

Precise Biometrics AB ("Precise" or the "Company") has prepared a prospectus by reason of the directed issue of up to 3,959,639 ordinary shares to Egis Technology Inc., the rights issue of up to 6,599,399 ordinary shares, and the over-allotment option of up to 2,339,787 ordinary shares, which were announced by the Company on 10 August 2022.

The prospectus has today on 6 September 2022 been approved and registered by the Swedish Financial Supervisory Authority ("SFSA"), and is available on the Company's website, www. precisebiometrics.com. The prospectus is also available on Vator Securities' website, www. vatorsecurities.se, and will within a couple of days also be published on the SFSA's prospectus register, https://fi.se/sv/vara-register/prospektregistret/.

The subscription period for the rights issue will run during the period from and including 12 September 2022 up to and including 26 September 2022. The last day for trading in the Company's share including the right to participate in the rights issue is today, 6 September 2022.

Advisors

Vator Securities AB acts as financial advisor and issuing agent to Precise Biometrics in connection with the share issues and Advokatfirman Lindahl KB is the Company's legal advisor in connection with the share issues.

For more information, please contact:

Patrick Höijer, CEO

E-mail: patrik.hoijer@precisebiometrics.com

This information was submitted for publication at 11:45 CEST on 6 September 2022.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction.



Any offer of securities in the Company mentioned in this press release will be made through a prospectus or with an applicable exemption in accordance with the Prospectus Regulation. This press release is not a prospectus according to Regulation (EU) 2017/1129 and Directive 2003/71 / EC (together with relevant implementations and delegated regulations "Prospectus Regulation").

No securities described herein have been, nor will they be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws in any other state or jurisdiction in the USA and no securities may be offered or transferred (as defined in Regulation S under the Securities Act), directly or indirectly, in or into the USA other than pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the USA. This press release does not constitute an offer or invitation to acquire or subscribe for shares or other securities in the USA. No securities will be offered to the public in the United States.

In the United Kingdom, this release is only being distributed to persons who are "Qualified Investors" within the meaning of Article 2(e) of Regulation (EU) 2017/1129 as it forms part of English law by virtue of the European Union (Withdrawal) Act 2018 (the "EUWA") who are (i) investment professionals within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) persons who falls within Article 49(2)(a) to (d) of the Order, or (iii) other persons to whom this release may lawfully be communicated.

Within the European Economic Area ("EEA"), no public offering of securities is made in other countries than Sweden. In other member states of the EU, such an offering of securities may only be made in accordance with an applicable exemption in the Prospectus Regulation (EU) 2017/1129.

About Us

Precise Biometrics AB (publ) ("Precise") is a global supplier of identification software. The company offers products in various areas of application that enable users – using their own biometrics – to identify themselves in a convenient and secure way. Precise has two business areas; Digital Identity and Algo, and operates out of its offices in Lund, Sweden, Potsdam NY, USA and Shanghai, China. The Precise share is listed at Nasdaq Stockholm (PREC). For more information, please visit www. precisebiometrics.com

Attachments

Precise Biometrics publishes prospectus